IL162469A0 - Process for affecting neurologic progression pharmacyclics, inc. - Google Patents
Process for affecting neurologic progression pharmacyclics, inc.Info
- Publication number
- IL162469A0 IL162469A0 IL16246902A IL16246902A IL162469A0 IL 162469 A0 IL162469 A0 IL 162469A0 IL 16246902 A IL16246902 A IL 16246902A IL 16246902 A IL16246902 A IL 16246902A IL 162469 A0 IL162469 A0 IL 162469A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmacyclics
- neurologic progression
- affecting
- affecting neurologic
- progression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33965001P | 2001-12-13 | 2001-12-13 | |
| US34658402P | 2002-01-07 | 2002-01-07 | |
| US35309002P | 2002-01-30 | 2002-01-30 | |
| PCT/US2002/039974 WO2003049731A1 (en) | 2001-12-13 | 2002-12-12 | Process for affecting neurologic progression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162469A0 true IL162469A0 (en) | 2005-11-20 |
Family
ID=27407352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16246902A IL162469A0 (en) | 2001-12-13 | 2002-12-12 | Process for affecting neurologic progression pharmacyclics, inc. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20030130252A1 (xx) |
| EP (1) | EP1465617B1 (xx) |
| JP (1) | JP2005511719A (xx) |
| KR (1) | KR20040075001A (xx) |
| CN (1) | CN1615129A (xx) |
| AT (1) | ATE411017T1 (xx) |
| AU (1) | AU2002364165B2 (xx) |
| CA (1) | CA2469613A1 (xx) |
| DE (1) | DE60229437D1 (xx) |
| DK (1) | DK1465617T3 (xx) |
| ES (1) | ES2315429T3 (xx) |
| IL (1) | IL162469A0 (xx) |
| MX (1) | MXPA04005715A (xx) |
| PL (1) | PL372326A1 (xx) |
| PT (1) | PT1465617E (xx) |
| WO (1) | WO2003049731A1 (xx) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1845998A4 (en) * | 2005-01-19 | 2008-06-18 | Pharmacyclics Inc | METHOD FOR TREATING NEUROLOGICAL DISEASES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252720A (en) * | 1989-03-06 | 1993-10-12 | Board Of Regents, The University Of Texas System | Metal complexes of water soluble texaphyrins |
| US5457183A (en) * | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5776925A (en) * | 1996-01-25 | 1998-07-07 | Pharmacyclics, Inc. | Methods for cancer chemosensitization |
| US6013646A (en) * | 1998-07-02 | 2000-01-11 | Bayer Corporation | Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
-
2002
- 2002-12-12 JP JP2003550780A patent/JP2005511719A/ja active Pending
- 2002-12-12 ES ES02799240T patent/ES2315429T3/es not_active Expired - Lifetime
- 2002-12-12 AT AT02799240T patent/ATE411017T1/de not_active IP Right Cessation
- 2002-12-12 CN CNA028270924A patent/CN1615129A/zh active Pending
- 2002-12-12 PL PL02372326A patent/PL372326A1/xx not_active Application Discontinuation
- 2002-12-12 AU AU2002364165A patent/AU2002364165B2/en not_active Ceased
- 2002-12-12 WO PCT/US2002/039974 patent/WO2003049731A1/en active Application Filing
- 2002-12-12 CA CA002469613A patent/CA2469613A1/en not_active Abandoned
- 2002-12-12 DE DE60229437T patent/DE60229437D1/de not_active Expired - Fee Related
- 2002-12-12 IL IL16246902A patent/IL162469A0/xx unknown
- 2002-12-12 DK DK02799240T patent/DK1465617T3/da active
- 2002-12-12 EP EP02799240A patent/EP1465617B1/en not_active Expired - Lifetime
- 2002-12-12 PT PT02799240T patent/PT1465617E/pt unknown
- 2002-12-12 KR KR10-2004-7009132A patent/KR20040075001A/ko not_active Application Discontinuation
- 2002-12-12 MX MXPA04005715A patent/MXPA04005715A/es not_active Application Discontinuation
- 2002-12-12 US US10/318,659 patent/US20030130252A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04005715A (es) | 2004-10-15 |
| EP1465617A4 (en) | 2005-10-12 |
| AU2002364165B2 (en) | 2007-09-20 |
| DE60229437D1 (de) | 2008-11-27 |
| PT1465617E (pt) | 2009-01-23 |
| WO2003049731A1 (en) | 2003-06-19 |
| KR20040075001A (ko) | 2004-08-26 |
| PL372326A1 (en) | 2005-07-11 |
| EP1465617A1 (en) | 2004-10-13 |
| AU2002364165A1 (en) | 2003-06-23 |
| EP1465617B1 (en) | 2008-10-15 |
| CN1615129A (zh) | 2005-05-11 |
| JP2005511719A (ja) | 2005-04-28 |
| ATE411017T1 (de) | 2008-10-15 |
| CA2469613A1 (en) | 2003-06-19 |
| US20030130252A1 (en) | 2003-07-10 |
| ES2315429T3 (es) | 2009-04-01 |
| DK1465617T3 (da) | 2009-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03011197A (es) | Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales. | |
| MXPA03006093A (es) | Derivados de n(fenilsulfonil)glicina y su uso terapeutico. | |
| HK1068626A1 (en) | Chemical compounds | |
| TW200508201A (en) | Novel process for the preparation of roflumilast | |
| RS20050810A (xx) | 5,7-diaminopirazolo(4,3-d)pirimidini korisni za lečenje hipertenzije | |
| MY134892A (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use | |
| PH12013500123A1 (en) | Hemiasterlin derivatives and uses thereof | |
| MY130718A (en) | Antitumor compounds and methods | |
| MXPA04000210A (es) | Conjugados quelantes mejorados. | |
| HK1063787A1 (en) | Novel ligand for nicotinic acetylcholine receptorsuseful in therapy | |
| PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
| HK1155664A1 (en) | Treatment of metastasized tumors | |
| GB2378948B (en) | Novel compounds for modulating cell proliferation | |
| HK1066213A1 (en) | Tricyclic imidazopyridines. | |
| TW200510398A (en) | Novel compounds | |
| MXPA03004986A (es) | Proceso para preparar polimeros de emulsion con alta pureza. | |
| IL162469A0 (en) | Process for affecting neurologic progression pharmacyclics, inc. | |
| MXPA04004090A (es) | Compuestos substituidos de 1h-quinolin-2-ona. | |
| EP1364652A4 (en) | CURE FOR LUNG CANCER | |
| RS16804A (xx) | Upotreba 4-piridilmetilftalazina u lečenju raka | |
| HU0201195D0 (xx) | ||
| DE60220504D1 (en) | Tryptasehemmer | |
| AU2002359762A1 (en) | Luminacin analogs and uses thereof | |
| IL159469A0 (en) | Xenogenic oligo-or/and polyribonucleotides as agents for the treatment of malignant tumours | |
| UA33493A (uk) | Розчин для кислотної обробки свердловин |